An in vitro model for disease-specific immunotherapy in myasthenia gravis using soluble MHC class II bound to AChR-derived peptide

Ann N Y Acad Sci. 1993 Jun 21:681:577-80. doi: 10.1111/j.1749-6632.1993.tb22946.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HLA-DR Antigens / chemistry*
  • Immunotherapy
  • In Vitro Techniques
  • Lymphocyte Activation
  • Myasthenia Gravis / therapy*
  • Receptors, Nicotinic / chemistry*
  • Receptors, Nicotinic / immunology
  • Solubility
  • T-Lymphocytes, Helper-Inducer / immunology*

Substances

  • HLA-DR Antigens
  • Receptors, Nicotinic